Surge in Options Trading for Dana, Akero, and Exelixis Stocks

Today, options trading activity highlights notable movements among components of the Russell 3000 index. Dana Inc (Symbol: DAN) leads with a total volume of 14,258 contracts traded, equating to around 1.4 million underlying shares. This trading volume represents 70.9% of DAN’s average daily trading volume over the past month, which stands at 2.0 million shares. A significant portion of today’s activity is attributed to the $17 strike call option expiring May 16, 2025, with 5,763 contracts trading, reflecting about 576,300 underlying shares of DAN.

Below is a chart showing DAN’s trailing twelve-month trading history, highlighting the $17 strike in orange:

In parallel, Akero Therapeutics Inc (Symbol: AKRO) has seen a trading volume of 7,470 contracts today, which corresponds to approximately 747,000 underlying shares. This figure accounts for a considerable 63.5% of AKRO’s average daily trading volume over the past month, pegged at 1.2 million shares. The $42.50 strike put option, also expiring May 16, 2025, generated notable interest, with 2,505 contracts trading, representing roughly 250,500 underlying shares of AKRO.

Below is a chart showing AKRO’s trailing twelve-month trading history, with the $42.50 strike highlighted in orange:

Exelixis Inc (Symbol: EXEL) is another company experiencing significant options trading today, with a total volume of 14,805 contracts. This translates to about 1.5 million underlying shares and around 62.6% of EXEL’s average daily trading volume of 2.4 million shares. The $45 strike call option expiring May 16, 2025, saw a high trading volume of 2,272 contracts, representing approximately 227,200 underlying shares of EXEL.

Below is a chart illustrating EXEL’s trailing twelve-month trading history, with the $45 strike marked in orange:

Investors interested in different expirations for options on DAN, AKRO, or EXEL can explore additional options at StockOptionsChannel.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.